PCDHGA11: A Promising Drug Target and Biomarker for Prostate Cancer

Target Name: PCDHGA11

NCBI ID: G56105

PCDHGA11

PCDHGA11: A Promising Drug Target and Biomarker for Prostate Cancer

Introduction

Prostate cancer is a leading cause of cancer-related deaths worldwide, with an estimated 1,380,000 new cases and 910,000 deaths in the United States alone in 2020. The majority of prostate cancers are sporadic, meaning they occur in individuals without a family history of the disease . However, a small percentage of cases are hereditary, known as hereditary prostate cancer. The most common hereditary form of prostate cancer is BAP1 cancer, which is associated with the gene PCDHGA11.

PCDHGA11 is a gene that encodes the protein protocadherin gamma A11 (PCGA11), which is a critical regulator of cell-cell adhesion. In individuals with PCDHGA11 mutations, cells may have increased or decreased adhesion, leading to a range of cellular behaviors that contribute to the development and progression of prostate cancer. As a result, targeting PCDHGA11 has the potential to be a valuable therapeutic approach for the treatment of prostate cancer.

The search for new drug targets and biomarkers in prostate cancer has led to the identification of numerous potential targets, including PCDHGA11. This gene has been shown to be involved in several key cellular processes that are relevant to the development and progression of prostate cancer.

PCDHGA11 and cell adhesion

PCDHGA11 is a member of the cadherin gene family, which includes several related genes that are involved in cell-cell adhesion. The cadherins are a family of transmembrane proteins that play a central role in cell-cell adhesion by promoting the formation of tight junctions and sealing gaps between adjacent cells.

In epithelial cells, cadherins help to maintain the integrity of the intercellular junctions that mediate tight cell-cell adhesion. In addition, cadherins are involved in the formation of the plasma membrane exosomes which is a structure that allows cells to deliver signaling molecules to neighboring cells.

PCDHGA11 and prostate cancer

Studies have shown that PCDHGA11 is involved in the development and progression of prostate cancer. Individuals with PCDHGA11 mutations may have increased or decreased adhesion, which can lead to the formation of more invasive and incurable tumors.

In addition, PCDHGA11 has also been shown to be involved in the regulation of prostate cell proliferation and the development of androgen independence in prostate cancer. It has been shown that reducing PCDHGA11 levels can inhibit the growth and survival of prostate cancer cells.

PCDHGA11 as a drug target

The potential of PCDHGA11 as a drug target is due to its involvement in several key cellular processes that are relevant to the development and progression of prostate cancer. To target PCDHGA11, researchers have developed several different approaches, including inhibition of its expression, activation of its downstream targets, and the use of small molecules and antibodies that specifically target PCDHGA11.

One approach to targeting PCDHGA11 is to use small molecules that can inhibit its expression or activity. For example, researchers have developed compounds that can inhibit the activity of PCDHGA11, leading to the collapse of intercellular junctions and the formation of more invasive tumors. These compounds have been shown to be effective in animal models of prostate cancer.

Another approach to targeting PCDHGA11 is to use antibodies that specifically recognize and target its protein. For example, researchers have developed antibodies that can bind to PCDH

Protein Name: Protocadherin Gamma Subfamily A, 11

Functions: Potential calcium-dependent cell-adhesion protein. May be involved in the establishment and maintenance of specific neuronal connections in the brain

The "PCDHGA11 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about PCDHGA11 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets